CISATRACURIUM BESYLATE INJECTION SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CISATRACURIUM (CISATRACURIUM BESYLATE)

可用日期:

MYLAN PHARMACEUTICALS ULC

ATC代码:

M03AC11

INN（国际名称）:

CISATRACURIUM

剂量:

2MG

药物剂型:

SOLUTION

组成:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

给药途径:

INTRAVENOUS

每包单位数:

10ML

处方类型:

Prescription

治疗领域:

NEUROMUSCULAR BLOCKING AGENTS

產品總結:

Active ingredient group (AIG) number: 0133260001; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2018-06-15

产品特点

_ Page 1 of 31 _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION
SOLUTION FOR INJECTION
2 MG/ML CISATRACURIUM (AS CISATRACURIUM BESYLATE)
10 ML MULTIPLE DOSE VIAL
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR
WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Preparation: August 18, 2014
Control No.: 176645
_ Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
9
DRUG INTERACTIONS
..........................................................................................................
10
DOSAGE AND ADMINISTRATION
......................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
16
STORAGE AND STABILITY
..................................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 24
PART II: SCIENTIFIC INFORMATION
................................................................................
25
PHARMACEUTICAL INFORMATION
...